Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-GD2 CAR-T cells coexpressing GITRL
- Development stage
- Preclinical
- Lead developer
- T Cell Nouveau
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-GD2 CAR-T cells coexpressing GITRL is an experimental cell therapy designed to treat solid tumors, specifically glioblastoma. It consists of T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the ganglioside GD2, along with the glucocorticoid-induced TNFR-related protein ligand (GITRL). The co-expression of GITRL is intended to enhance CAR-T cell potency by engaging the GITR receptor, which promotes T-cell activation, reduces exhaustion (lowering PD-1 and LAG-3 expression), and counteracts the immunosuppressive effects of regulatory T cells (Tregs) within the tumor microenvironment. Preclinical studies in glioblastoma models have demonstrated improved functional persistence and metabolic characteristics compared to standard anti-GD2 CAR-T cells.
- Other names
- anti-GD2 chimeric antigen receptor T cells coexpressing GITR ligandanti-GD-2 chimeric antigen receptor T cells coexpressing GITR ligandanti-GD 2 chimeric antigen receptor T cells coexpressing GITR ligandGD2-GITRL CAR-TGD-2-GITRL CAR-TGD 2-GITRL CAR-T
02
Targets
GD2TNFRSF18 (GITR)
Beyond the preview
Go deeper on anti-GD2 CAR-T cells coexpressing GITRL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-GD2 CAR-T cells coexpressing GITRL.